Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00533117 · ClinicalTrials.gov registry record · Phase 4
Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT00533117: Completed Phase 4 study, sponsored by New York State Psychiatric Institute.
NCT00533117 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 91 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00533117, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.
Primary Outcome
Suicide attempt count total over the course of the 12 month treatment period (sum of 6 bimonthly assessments during the treatment phase)
Interventions
- BEHAVIORAL Dialectical Behavior Therapy
- DRUG Fluoxetine
- BEHAVIORAL Supportive psychotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2001-03 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT00533117 record still lists
NCT00533117 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 3 interventions - of which Dialectical Behavior Therapy is the first listed.
NCT00533117 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00533117 about?
NCT00533117 is a clinical study titled "Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder". This study will determine whether dialectical behavior therapy and fluoxetine are more effective combined or alone in treating people with borderline personality disorder.
What is the current status of trial NCT00533117?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2001-03. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00533117?
The interventions under investigation include: Dialectical Behavior Therapy (BEHAVIORAL), Fluoxetine (DRUG), Supportive psychotherapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00533117?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00533117's enrollment target sits among peer trials
91 884th of 2000 higher than 1,115 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia